Trial Profile
An Open, Randomized, Multi-center, Phase 2 Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix: the Efficacy and New Biomarkers
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Tamoxifen (Primary)
- Indications Cervical cancer
- Focus Biomarker; Therapeutic Use
- 02 Jul 2015 New trial record